Interleukin-6-Producing Pheochromocytoma

Suzuki, Kenshi; Miyashita, Akiko; Inoue, Y.; Iki, Seiko; Enomoto, Hidetoshi; Takahashi, Yuji; Takemura, Tamiko

doi:10.1159/000204897

Cited by 39 publications

(42 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic inflammatory syndrome has been reported to be associated with IL-6 producing pheochromocytoma [5][6][7][8][9][10]. Patients with this condition invariably had fever, which responded well to non-steroidal antiinflammatory drugs (NSAID) and steroids.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Inflammatory Syndrome and Hepatic Inflammatory Cell Infiltration Caused by an Interleukin-6 Producing Pheochromocytoma

et al. 2005

View full text Add to dashboard Cite

Abstract. Pheochromocytoma is a tumor that produces a variety of biologically active substances in addition to catecholamines. We report here a patient with a pheochromocytoma, who presented with acute inflammatory symptoms and marked abnormalities in liver function and hematological tests. A 31-year-old man, who had experienced intermittent fever, chills and weight 1oss during the previous several months, was referred to our hospital for further evaluation. Laboratory examination revealed anemia, leukocytosis with elevated inflammatory markers, and abnormalities in coagulation and liver function tests. Histological examination revealed a marked plasmacytosis in the bone marrow and lymphocyte infiltration into the portal area of the liver. Along with increases in serum catecholamine and urine catecholamine metabolites, his serum interleukin (IL)-6 level was increased to 300 pg/ml, compared with a normal range of 3-12 pg/ml. Left adrenalectomy was performed. The adrenal tumor was densely immunostained with antibody to IL-6. After resection of his adrenal tumor, his serum IL-6 level returned to normal (11 pg/ml) and all symptoms subsided with normalization of laboratory findings.

show abstract

Section: Discussionmentioning

confidence: 99%

“…To date, six cases of IL-6-producing pheochromocytoma have been described, all of which presented with fever and acute inflammatory symptoms [5][6][7][8][9][10]. We report here a case of IL-6 producing pheochromocytoma, which caused systemic inflammatory responses and hepatic inflammatory cell infiltration.…”

mentioning

confidence: 85%

Systemic Inflammatory Syndrome and Hepatic Inflammatory Cell Infiltration Caused by an Interleukin-6 Producing Pheochromocytoma

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Both mesothelioma and tuberculous pleurisy patients had significantly higher pleural IL-6 levels and platelet counts than patients with lung adenocarcinoma and cytology-positive pleural effusion. Pheochromocytoma and liposarcoma are examples of IL-6-producing tumours with associated thrombocytosis (Nagasawa et al, 1990;Suzuki et al, 1991). In some other diseases, such as rheumatoid arthritis and cardiac myxoma, and in burmed patients, the elevation of serum IL-6 levels has also been demonstrated (Holt et al, 1991;Jourdan et al, 1991;Nijsten et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

Nakano

Chahinian²,

Shinjo³

et al. 1998

Br J Cancer

115

View full text Add to dashboard Cite

SummaryThe relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, a,-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.

show abstract

“…A PNS presenting with fever and increased acute phase proteins has been shown to be associated with elevated IL-6 levels (Dawson & Harding 1982, Yoshizaki et al 1989, Fukumoto et al 1991 and related tumours to secrete IL-6 (Tabibzadeh et al 1989, Fukumoto et al 1991. In this context, several patients with phaeochromocytoma, pyrexia, marked inflammatory signs and elevated IL-6 levels have been described, in all of whom symptoms subsided by removal of the tumour; IL-6 expression was demonstrated in the tumours (Fukumoto et al 1991, Suzuki et al 1991. A case of co-secretion of ACTH and IL-6 has been described, implicating a stimulatory effect of IL-6 on ACTH secretion (Suzuki et al 1991).…”

Section: Cytokinesmentioning

confidence: 99%

“…In this context, several patients with phaeochromocytoma, pyrexia, marked inflammatory signs and elevated IL-6 levels have been described, in all of whom symptoms subsided by removal of the tumour; IL-6 expression was demonstrated in the tumours (Fukumoto et al 1991, Suzuki et al 1991. A case of co-secretion of ACTH and IL-6 has been described, implicating a stimulatory effect of IL-6 on ACTH secretion (Suzuki et al 1991). Hypoglycaemia occurring in patients with metastatic disease has not been clearly defined and is usually attributed to liver infiltration and failure by the tumour ).…”

Section: Cytokinesmentioning

confidence: 99%

Paraneoplastic syndromes secondary to neuroendocrine tumours

Kaltsas

Androulakis²,

Herder³

et al. 2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes. The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms. Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia. Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression. PNSs can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required. Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours. Clinical awareness and the incorporation into clinical practise of 111 In-octreotide scintigraphy, chromogranin A and other evolving biochemical marker measurement techniques have substantially contributed to the identification of patients harbouring such syndromes. Diseasespecific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth. Owing to their rarity, central registration of these syndromes is very helpful in order to be able to provide evidence-based diagnostic and therapeutic approaches.

show abstract

Interleukin-6-Producing Pheochromocytoma

Cited by 39 publications

References 3 publications

Systemic Inflammatory Syndrome and Hepatic Inflammatory Cell Infiltration Caused by an Interleukin-6 Producing Pheochromocytoma

Systemic Inflammatory Syndrome and Hepatic Inflammatory Cell Infiltration Caused by an Interleukin-6 Producing Pheochromocytoma

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

Paraneoplastic syndromes secondary to neuroendocrine tumours

Contact Info

Product

Resources

About